Dianthus Therapeutics, Inc.

We asked our team how they’d describe Dianthus,  take a look at some of their responses! For the second year in a row, the top 3 words were Open, Collaborative, and Supportive, with two new additions, Motivated and Ambitious! As our company evolves, we aim to continue cultivating an environment where our employees thrive and #GrowTogether. Visit dianthustx.com/careers to learn more about our mission, culture, and opportunities to join our team! #biotech #teamwork #employeeengagement

Happy Independence Day! We wish everyone a safe and joyous holiday.

Dianthus gets it - from 100% remote work flexibility to summer & winter shutdowns. If we’ve worked together & you’re looking for a new role in biostats, DM me.

🚨 Hot Job Alert! 🚨 We are #hiring a Senior Director, Biostatistics. You will be developing and executing our #biostats strategy for multiple clinical programs as we advance the development of next-generation antibody #ComplementTherapeutics. To join us, learn more and #apply here: https://lnkd.in/edk9Fb4a

We are excited to announce two poster presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN) in Helsinki.   June 29, 2024, 14:10 EEST DNTH103, Investigational Therapy for Generalised Myasthenia Gravis Session: Muscle and Neuromuscular Junction Disorder 1; Presentation Number: EPR-118 June 30, 2024, 14:25 EEST DNTH103: Preventing Nerve Damage in a CIDP Model via Sustained Complement Inhibition Session: Muscle and Neuromuscular Junction Disorder 2; Presentation Number: EPR-243 These posters will be made available after they are presented on the Dianthus website: https://lnkd.in/gZz2x_tw DNTH103 is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide. #ean2024 #neurology

We are always looking for the most passionate and innovative individuals, so our team comes from all over the nation! With our combination of #remote and #hybrid roles, our team now spans across 11 states, including two team members across the pond. Look out for our Hot Job Alerts and visit dianthustx.com/careers to learn more about how we #GrowTogether! #hiring #biotechjobs #GrowWithUs

As a chronic neuromuscular disease, #MyastheniaGravis causes weakness in the voluntary muscles. It affects both men and women and occurs across all racial and ethnic groups. We are #MGStrong and committed to advancing the next generation of #ComplementTherapeutics with the potential to treat patients living with generalized Myasthenia Gravis.

A big thanks to our CPO Kristina M. for driving our Learning & Development, alongside Results By Design®, LLC and Ted Higgins who facilitated our recent training on the Fundamentals of Presentation Design! It was a great opportunity to discuss tactics on how to be more efficient and compelling presenters. #biotech #skillbuilding #TeamDianthus

We are excited to announce we received FDA clearance of our Phase 2 Investigational New Drug (IND) application for the MoMeNtum trial of DNTH103 in patients with Multifocal Motor Neuropathy (MMN). Top-line results are expected to be available in the second half of 2026. Learn more: https://lnkd.in/ggZZeSfZ #biotech #MMN

June is #MyastheniaGravis (MG) Awareness Month! At Dianthus, we are raising awareness for the advocates, patients, and caregivers in the MG community. #MGStrong